Artrya (ASX:AYA) said that the Huntsville Hospital Heart Centre has agreed to participate in the company's SAPPHIRE study, which is to be conducted in three phases, to identify high-risk coronary artery disease patients with greater precision than traditional risk models, according to a Tuesday filing with the Australian bourse.
The company expects to launch the study in early 2026, the filing said.